WallStreetZenWallStreetZen

NASDAQ: LGND
Ligand Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LGND

Based on 8 analysts offering 12 month price targets for Ligand Pharmaceuticals Inc

Min Forecast
$326.00+3.98%
Avg Forecast
$354.13+12.95%
Max Forecast
$397.00+26.63%

Should I buy or sell LGND stock?

Based on 8 analysts offering ratings for Ligand Pharmaceuticals Inc.

Strong Buy
Strong Buy
4 analysts 50%
Buy
4 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LGND's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates LGND as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their LGND stock forecasts and price targets.

LGND stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-30
lockedlocked$00.00+00.00%2026-09-25
lockedlocked$00.00+00.00%2026-09-24
lockedlocked$00.00+00.00%2026-09-23Find Out Why
lockedlocked$00.00+00.00%2026-08-14
Oppenheimer
Top 4%
97
BuyReiterates$326.00+3.98%2026-08-03
Bank of America
Top 9%
92
Strong BuyMaintains$388.00+23.76%2026-07-09Find out why
Stifel Nicolaus
Top 8%
93
Strong BuyMaintains$332.00+5.89%2026-07-08Find out why

1 of 1

Forecast return on equity

Is LGND forecast to generate an efficient return?

Company
29.3%
Industry
14.98%
Market
172.55%
LGND's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LGND forecast to generate an efficient return on assets?

Company
12.59%
Industry
21.21%
LGND is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LGND earnings per share forecast

What is LGND's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$9.61+262.54%
Avg 2 year Forecast
$12.44+369.3%
Avg 3 year Forecast
$14.92+463%
LGND's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

LGND revenue forecast

What is LGND's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$294.4M+15.97%
Avg 2 year Forecast
$388.7M+53.14%
Avg 3 year Forecast
$450.7M+77.57%
LGND's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LGND earnings growth forecast

How is LGND forecast to perform vs Biotechnology companies and vs the US market?

Company
78.21%
Industry
12.77%
Market
32.33%
LGND's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
LGND's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
LGND's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

LGND revenue growth forecast

How is LGND forecast to perform vs Biotechnology companies and vs the US market?

Company
21.69%
Industry
29.34%
Market
12.56%
LGND's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LGND's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LGND vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LGND$313.52$354.13+12.95%Strong Buy
KOD$98.89$92.33-6.63%Strong Buy
IMVT$29.04$47.67+64.14%Strong Buy
BLTE$152.17$251.60+65.34%Strong Buy
RYTM$86.44$141.89+64.15%Strong Buy
View Top Biotech Stocks

Ligand Pharmaceuticals Stock Forecast FAQ

Is Ligand Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: LGND) stock is to Strong Buy LGND stock.

Out of 8 analysts, 4 (50%) are recommending LGND as a Strong Buy, 4 (50%) are recommending LGND as a Buy, 0 (0%) are recommending LGND as a Hold, 0 (0%) are recommending LGND as a Sell, and 0 (0%) are recommending LGND as a Strong Sell.

If you're new to stock investing, here's how to buy Ligand Pharmaceuticals stock.

What is LGND's earnings growth forecast for 2026-2028?

(NASDAQ: LGND) Ligand Pharmaceuticals's forecast annual earnings growth rate of 78.21% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.77%, and it is also forecast to beat the US market's average forecast earnings growth rate of 32.33%.

Ligand Pharmaceuticals's earnings in 2026 is $51,462,000.On average, 14 Wall Street analysts forecast LGND's earnings for 2026 to be $192,174,687, with the lowest LGND earnings forecast at $172,309,722, and the highest LGND earnings forecast at $203,520,381. On average, 13 Wall Street analysts forecast LGND's earnings for 2027 to be $248,767,135, with the lowest LGND earnings forecast at $206,026,755, and the highest LGND earnings forecast at $282,618,189.

In 2028, LGND is forecast to generate $298,432,549 in earnings, with the lowest earnings forecast at $248,957,164 and the highest earnings forecast at $345,249,538.

What is LGND's revenue growth forecast for 2026-2028?

(NASDAQ: LGND) Ligand Pharmaceuticals's forecast annual revenue growth rate of 21.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.34%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.56%.

Ligand Pharmaceuticals's revenue in 2026 is $253,827,000.On average, 14 Wall Street analysts forecast LGND's revenue for 2026 to be $5,888,078,959, with the lowest LGND revenue forecast at $5,445,612,909, and the highest LGND revenue forecast at $6,436,960,895. On average, 13 Wall Street analysts forecast LGND's revenue for 2027 to be $7,775,160,658, with the lowest LGND revenue forecast at $6,888,228,259, and the highest LGND revenue forecast at $8,563,478,336.

In 2028, LGND is forecast to generate $9,015,545,820 in revenue, with the lowest revenue forecast at $7,603,134,979 and the highest revenue forecast at $10,089,906,198.

What is LGND's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: LGND) forecast ROA is 12.59%, which is lower than the forecast US Biotechnology industry average of 21.21%.

What is LGND's Price Target?

According to 8 Wall Street analysts that have issued a 1 year LGND price target, the average LGND price target is $354.13, with the highest LGND stock price forecast at $397.00 and the lowest LGND stock price forecast at $326.00.

On average, Wall Street analysts predict that Ligand Pharmaceuticals's share price could reach $354.13 by Oct 30, 2027. The average Ligand Pharmaceuticals stock price prediction forecasts a potential upside of 12.95% from the current LGND share price of $313.52.

What is LGND's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: LGND) Ligand Pharmaceuticals's current Earnings Per Share (EPS) is $2.65. On average, analysts forecast that LGND's EPS will be $9.61 for 2026, with the lowest EPS forecast at $8.61, and the highest EPS forecast at $10.17. On average, analysts forecast that LGND's EPS will be $12.44 for 2027, with the lowest EPS forecast at $10.30, and the highest EPS forecast at $14.13. In 2028, LGND's EPS is forecast to hit $14.92 (min: $12.45, max: $17.26).

What is LGND's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: LGND) forecast ROE is 29.3%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.